中线-1通过mTOR/微管道调节实验性自身免疫脑膜炎中的T细胞活性
Yingying Wei1,2, Wenjuan Li1, Jie Huang1
1Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Theranostics
|February 7, 2024
概括
中线-1 (Mid1) 调节实验性自身免疫脑膜炎 (EAE) 中的效应T细胞迁移,这是多发性硬化症 (MS) 的一种模型. 破坏Mid1会减少T细胞向中枢神经系统的迁移,为MS提供潜在的治疗点.
科学领域:
- 神经免疫学 神经免疫学
- 细胞和分子免疫学 细胞和分子免疫学
- 自免疫性疾病的发病因子 发病因子
背景情况:
- 在诸如多发性硬化症 (MS) 等自身免疫性疾病中,T细胞迁移至关重要.
- 目前的疗法针对的是T细胞激活或细胞因子,而不是T细胞迁移.
- 对T细胞迁移调节的有限理解阻碍了治疗的发展.
研究的目的:
- 为了研究中线-1 (Mid1) 在效应体T细胞迁移中的作用.
- 探索Mid1作为MS治疗的潜在治疗标.
主要方法:
- 使用CRISPR-Cas9.9生成了Mid1淘汰赛小鼠.
- 通过活性免疫或收养转移诱导的实验性自身免疫脑膜炎 (EAE).
- 评估T细胞迁移使用体外Transwell测定和体内足台注射.
主要成果:
- 在EAE期间, Mid1表达在脊髓中增加.
- 在T细胞中Mid1的干扰抑制了EAE的发展,并减少了中枢神经系统T细胞的透.
- 在体外和体内,Mid1缺乏抑制了T细胞迁移,与mTOR/微管道相关.
结论:
- 在EAE中,Mid1是T细胞向中枢神经系统迁移的关键调节者.
- 中1mTOR/微管道为MS提供了一个新的治疗点.
更多相关视频
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
7.7K
09:01Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
Published on: November 17, 2020
7.1K
相关概念视频
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...